Arcus Biosciences, Inc.

Day range

$17.79 – $18.62

Open

$18.37

Prev close

$18.54

Volume

1.41M

Market cap

$2.36B

Shares out

127.33M

P/E

—

P/S

20.18

P/B

5.09

P/FCF

—

ROE

-99.1%

ROA

-49.8%

Debt/Equity

0.22

Div yield

0.00%

As of Oct 23, 2026

• Underwriting agreementOct 23, 2026

  On October 21, 2026, Arcus Biosciences, Inc. ... entered into an underwriting agreement ... with Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters ... relating to the public offering, issuance and sale of 14,285,715 shares of the Company's common stock.

• Preliminary resultsOct 21, 2026

  Based upon preliminary estimates and information available to Arcus Biosciences, Inc. (the "Company") as of October 21, 2026, the Company estimates that it had approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. This estimate ... is preliminary and subject to completion of the Company's financial closing procedures, including the completion of management's reviews.

• Clinical trial resultsOct 20, 2026

  Casdatifan monotherapy (n=121): with 28 months of median follow up in the four pooled monotherapy cohorts, median overall survival was 35 months, median PFS was 13 months and cORR was 36%.

• Annual meeting resultsJun 12, 2026

  On June 11, 2026, Arcus Biosciences, Inc. (the "Company") held its annual meeting of stockholders. The results of the stockholder votes on each proposal brought before the Annual Meeting is as follows: Proposal 1: The election of Class II directors... Proposal 2: The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm... Proposal 3: The approval, on an advisory basis, of the compensation of the Company's named executive officers...

• Partnership or collaborationApr 20, 2026

  On April 20, 2026, the Company announced that the period for Gilead's option rights under the Option, License and Collaboration Agreement entered into between the Company and Gilead in 2020, as amended, will end on July 14, 2026, following Gilead's decision to not make the option continuation payment to the Company.

Days to cover

7.6

Short interest

13.11M

Avg volume

1.72M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
  positiveZacks Investment Research· Oct 21, 2026
• Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
  positiveZacks Investment Research· Oct 21, 2026
• An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run
  neutralThe Motley Fool· Jul 13, 2026
• Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend
  positiveBenzinga· Dec 2, 2024
• Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033
  positiveGlobeNewswire Inc.· Aug 23, 2024